Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GND-04
- Development stage
- Preclinical
- Lead developer
- Gandeeva Therapeutics
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
01
Overview
GND-04 is a preclinical-stage therapeutic candidate being developed by Gandeeva Therapeutics for the treatment of unspecified oncology indications. It is part of the company's proprietary iGlue™ platform, which utilizes an AI-driven cryo-electron microscopy (cryo-EM) engine to design molecular glues. These "iGlues" are designed to stabilize or induce protein-protein interactions, targeting proteins that were previously considered "undruggable" or inaccessible. As of early 2024, GND-04 is in the discovery and optimization phase, with its specific molecular target and mechanism of action (beyond being a molecular glue) not yet publicly disclosed.
Beyond the preview
Go deeper on GND-04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GND-04.